IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v47y2024i5d10.1007_s40264-024-01409-5.html
   My bibliography  Save this article

Using Social Media as a Source of Real-World Data for Pharmaceutical Drug Development and Regulatory Decision Making

Author

Listed:
  • Didrik Wessel

    (Copenhagen Business School)

  • Nicolai Pogrebnyakov

    (Copenhagen Business School)

Abstract

Introduction While pharmaceutical companies aim to leverage real-world data (RWD) to bridge the gap between clinical drug development and real-world patient outcomes, extant research has mainly focused on the use of social media in a post-approval safety-surveillance setting. Recent regulatory and technological developments indicate that social media may serve as a rich source to expand the evidence base to pre-approval and drug development activities. However, use cases related to drug development have been largely omitted, thereby missing some of the benefits of RWD. In addition, an applied end-to-end understanding of RWD rooted in both industry and regulations is lacking. Objective We aimed to investigate how social media can be used as a source of RWD to support regulatory decision making and drug development in the pharmaceutical industry. We aimed to specifically explore the data pipeline and examine how social-media derived RWD can align with regulatory guidance from the US Food and Drug Administration and industry needs. Methods A machine learning pipeline was developed to extract patient insights related to anticoagulants from X (Twitter) data. These findings were then analysed from an industry perspective, and complemented by interviews with professionals from a pharmaceutical company. Results The analysis reveals several use cases where RWD derived from social media can be beneficial, particularly in generating hypotheses around patient and therapeutic area needs. We also note certain limitations of social media data, particularly around inferring causality. Conclusions Social media display considerable potential as a source of RWD for guiding efforts in pharmaceutical drug development and pre-approval settings. Although further regulatory guidance on the use of social media for RWD is needed to encourage its use, regulatory and technological developments are suggested to warrant at least exploratory uses for drug development.

Suggested Citation

  • Didrik Wessel & Nicolai Pogrebnyakov, 2024. "Using Social Media as a Source of Real-World Data for Pharmaceutical Drug Development and Regulatory Decision Making," Drug Safety, Springer, vol. 47(5), pages 495-511, May.
  • Handle: RePEc:spr:drugsa:v:47:y:2024:i:5:d:10.1007_s40264-024-01409-5
    DOI: 10.1007/s40264-024-01409-5
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-024-01409-5
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40264-024-01409-5?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Patricia GarcĂ­a-Abeijon & Catarina Costa & Margarita Taracido & Maria Teresa Herdeiro & Carla Torre & Adolfo Figueiras, 2023. "Factors Associated with Underreporting of Adverse Drug Reactions by Health Care Professionals: A Systematic Review Update," Drug Safety, Springer, vol. 46(7), pages 625-636, July.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.

      More about this item

      Statistics

      Access and download statistics

      Corrections

      All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:47:y:2024:i:5:d:10.1007_s40264-024-01409-5. See general information about how to correct material in RePEc.

      If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

      If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

      If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

      For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

      Please note that corrections may take a couple of weeks to filter through the various RePEc services.

      IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.